Effect of 3-Hydroxy-3-Methyl-Glutaryl-Coenzyme A Reductase Inhibitors on the Meibomian Gland Morphology in Patients with Dyslipidemia

Kuan-I Wu,Chin-Ying Chen,Tzuu-Shuh Jou,Jyh-Ming Jimmy Juang,Jin-Ying Lu,I-Jong Wang
DOI: https://doi.org/10.1016/j.ajo.2020.06.029
IF: 5.488
2020-11-01
American Journal of Ophthalmology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>Prior studies suggested an association between dyslipidemia and meibomian gland dysfunction (MGD). The aim of this prospective, non-randomized clinical study is to evaluate the possible association of dyslipidemia and its treatment with meibomian gland (MG) morphological changes by standardized meibography.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Design</h3><p>Prospective, non-randomized clinical study</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Two groups of participants were enrolled: group 1, patients under regular <u>3-hydroxy-3-methyl-glutaryl-coenzyme A (</u>HMG-CoA) reductase inhibitor (statin) treatment for dyslipidemia, and the group 2, those with newly diagnosed dyslipidemia who were under lifestyle interventions. Meibography was performed at baseline, 6-months and 12-month visits, and graded by meiboscores. Participants underwent slit lamp examination for signs of changes in meibum quality and MG lid morphological features. Ocular Surface Disease Index (OSDI) questionnaire was given to measure subjective symptoms of ocular surface disease. Dry eye parameters including tear meniscus height, non-invasive first and average tear film break-up time, and Schirmer's test results were also recorded.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>A total of 98 participants completed this longitudinal study over 12 months. There were statistically significant changes in total meiboscores (<em>P</em> = 0.01) and upper eyelid meiboscores (<em>P</em> = 0.012), lid margin abnormality scores (<em>P</em> = 0.0059) and meibum quality (<em>P</em> = 0.0002) in the statin group during follow-up visits. Similar changes of upper eyelid meiboscores (<em>P</em> = 0.046) and meibum quality (<em>P</em> = 0.046) were noted in the non-statin group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Meibomian gland atrophy and deterioration of meibum quality continued in the long term among participants with dyslipidemia even under statin usage.</p>
ophthalmology
What problem does this paper attempt to address?